NCT02419755: Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies |
|
|
| Terminated | 2 | 12 | US | Bortezomib, Velcade, PS-341, MLN341, LDP-341, Vorinostat, Zolinza, Suberoylanilide Hydroxamic Acid, SAHA, Mitoxantrone, Novantrone, Cytarabine, Ara-C, Cytosar, Methotrexate, ITMHA, Intrathecal Triples, Hydrocortisone, Peg-L-Asparaginase, Pegaspargase, Oncaspar, Erwinia L-Asparaginase, Erwinase, Dexamethasone, Decadron, Mercaptopurine, 6-MP, Purinethol, Doxorubicin, Adriamycin® | St. Jude Children's Research Hospital | Mixed Lineage Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoid Leukemia | 12/16 | 12/16 | | |
NCT01692197: E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes |
|
|
| Completed | 2 | 43 | US | E7070, Idarubicin, Idamycin, Cytarabine, ARA-C, Cytosar, DepoCyt, Cytosine Arabinosine Hydrochloride, Dexamethasone, Decadron | M.D. Anderson Cancer Center, Eisai Inc. | Leukemia | 06/17 | 06/17 | | |
